Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsGlobeNewsWire • 02/02/24
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 02/02/24
Gear Up for Regeneron (REGN) Q4 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 01/30/24
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical ProgramsGlobeNewsWire • 01/30/24
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)GlobeNewsWire • 01/25/24
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)GlobeNewsWire • 01/25/24
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in AwardsPRNewsWire • 01/24/24
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot InvolvementGlobeNewsWire • 01/16/24
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — AgainInvestors Business Daily • 01/12/24